Horsholm, Denmark, June 26, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the Francis Crick Institute, London, United Kingdom, has agreed to amend the Research License Agreement about ExpreS2ion’s proprietary ExpreS2 expression system for another year.
The Research License Agreement
In July 2015 ExpreS2ion and the Francis Crick Institute entered into a one-year Research License Agreement whereby The Francis Crick Institute was granted access to research based on ExpreS2ion’s proprietary ExpreS2 system. The Research License Agreement is now amended to be effective for a third full year term. ExpreS2ion and The Francis Crick Institute are not disclosing any terms for extending the Research License Agreement.
About the Francis Crick Institute
The Francis Crick Institute is a biomedical discovery institute which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under a single roof in Europe working in areas as cancer, heart disease, stroke, infections, and neurodegenerative diseases. The Francis Crick Institute was founded by six of the UK’s most successful scientific and academic organisations – the Medical Research Council (MRC), Cancer Research UK (CRUK), the Wellcome Trust, UCL (University College London), Imperial College London and King’s College London. For more information, please visit: www.crick.ac.uk